Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of oral difelikefalin (CR845) for moderate to severe pruritus in subjects with atopic dermatitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Pruritus

Drugs mentioned

• Difelikefalin (CR845) (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Pruritus, Atopic Dermatitis | Phase 2 | Status: COMPLETED